Epigenetic suppression of human telomerase ( hTERT ) is mediated by the metastasis suppressor NME2 in a G-quadruplex–dependent fashion by Saha, Dhurjhoti et al.
Epigenetic suppression of human telomerase (hTERT) is
mediated by the metastasis suppressor NME2 in a
G-quadruplex–dependent fashion
Received for publication,April 20, 2017, and in revised form, July 17, 2017 Published, Papers in Press, July 17, 2017, DOI 10.1074/jbc.M117.792077
Dhurjhoti Saha‡1, Ankita Singh‡1,2, Tabish Hussain‡, Vivek Srivastava‡3, Suman Sengupta‡, Anirban Kar‡4,
Parashar Dhapola§, Vishnu Dhople¶5, Ramesh Ummanni¶, and Shantanu Chowdhury‡§6
From the ‡Genomics andMolecular Medicine Unit, §G.N.R. Knowledge Centre for Genome Informatics, and Academy of Scientific &
Innovative Research (AcSIR), CSIR-Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research
(CSIR), Mathura Road, NewDelhi 110025, India and ¶Centre for Chemical Biology, CSIR-Indian Institute of Chemical Technology,
Hyderabad 500007, India
Edited by Joel Gottesfeld
Transcriptional activation of the human telomerase re-
verse transcriptase (hTERT) gene, which remains repressed
in adult somatic cells, is critical during tumorigenesis. Sev-
eral transcription factors and the epigenetic state of the
hTERT promoter are known to be important for tight control
of hTERT in normal tissues, but the molecular mechanisms
leading to hTERT reactivation in cancer are not well-under-
stood. Surprisingly, here we found occupancy of the metasta-
sis suppressor non-metastatic 2 (NME2) within the hTERT
core promoter in HT1080 fibrosarcoma cells and HCT116
colon cancer cells and NME2-mediated transcriptional
repression of hTERT in these cells. We also report that loss of
NME2 results in up-regulated hTERT expression. Mechanis-
tically, additional results indicated that the RE1-silencing
transcription factor (REST)–lysine-specific histone demeth-
ylase 1 (LSD1) co-repressor complex associates with the
hTERT promoter in an NME2-dependent way and that this
assembly is required for maintaining repressive chromatin at
the hTERT promoter. Interestingly, a G-quadruplex motif at
the hTERT promoter was essential for occupancy of NME2
and the REST repressor complex on the hTERT promoter. In
light of this mechanistic insight, we studied the effects of
G-quadruplex–binding ligands on hTERT expression and
observed that several of these ligands repressed hTERT
expression. Together, our results support a mechanism of
hTERT epigenetic control involving a G-quadruplex pro-
moter motif, which potentially can be targeted by tailored
small molecules.
Specialized DNA–protein assemblies called telomeres
protect chromosome ends from being detected as DNA
breaks
(1, 2). The ribonucleoprotein telomerase adds de novo repeats
at the end of telomeres tomaintain telomere length (3). Human
telomerase comprises the catalytic reverse transcriptase
(hTERT)7 and an RNA component (hTR) that provides the
template for addition of telomeric repeats (4, 5). Lack of telom-
erase results in shortening of telomeres because of the end rep-
lication problem (6), and cells with critically short telomeres
activate the DNA damage response, leading to cell cycle arrest
or apoptosis (7, 8). This is the case inmost normal somatic cells,
which lack telomerase. Most cancer cells, however, have high
levels of telomerase, and telomere length is maintained for
initiation and survival of tumors (9). In normal cells, the
limiting factor for telomerase activity is the level of hTERT
mRNA, which is under strong transcriptional control (10). In
contrast, in about 85% of all cancers, hTERT expression is
reactivated (11), leading to malignant transformation and
aggressive metastasis in many cases (12). The molecular
mechanisms that underlie hTERT reactivation from other-
wise tight transcriptional control in normal somatic cells
remain poorly understood.
In this context, the metastasis suppressor non-metastatic 2
(NME2; also known as nm23-H2) is of interest (13). Human
nm23 has several isoforms; of these, H1 (or NME1) and H2 are
the most studied (14–16). The role of NME2 in metastases
suppression is well-described: overexpression of NME2 results
in reduced metastasis of human oral squamous carcinoma,
breast carcinoma, andmurinemelanoma cells (17–19), and the
level of NME2 expression negatively correlates with advanced/
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metastatic stages in several tumor types (20). Notably, indepen-
dent studies reported NME2-mediated transcription regula-
tion of c-myc where association of NME2 to a G-rich sequence
motif within the nuclease-hypersensitive element of the c-myc
promoter was revealed (21). NME2 was also reported to regu-
late PDGF-A and vinculin transcriptionally, supporting its role
as a regulatory factor (22, 23).
Herein we show that transcription of hTERT remains
repressed in the presence of NME2, and loss of NME2 results in
up-regulation of hTERT expression. NME2 binds to the hTERT
core promoter, and the REST repressor complex associates
with the hTERT promoter in an NME2-dependent manner.
Results also revealed that the presence of an intact G-rich DNA
secondary structure G-quadruplex (G4) motif in the hTERT
core promoter was required for association of NME2 and the
REST repressor complex at the hTERT promoter. Notably, in
the presence of NME2 and the REST repressor complex, epige-
netic alterations restricted permissiveness of the hTERT pro-
moter. Because altered NME2 has been detected in multiple
cancer tissues (14, 17–19), it is of interest to understand the
mechanisms underlying low NME2 and enhanced hTERT
expression/activation.
Results
NME2 associates with the hTERT core promoter and
transcriptionally represses hTERT
We noted a putative NME2-binding site on the hTERT core
promoter based on a previously reported motif from NME2
chromatin immunoprecipitation (ChIP)-sequencing experi-
ments (24). Here we performedChIP-PCR, with primers (span-
ning from 40 to 230 bp with respect to the hTERT tran-
scription start site) flanking the putative NME2-binding site,
first in HT1080 fibrosarcoma cells and then in HCT116 colon
cancer cells to confirm NME2 occupancy at the hTERT pro-
moter (Fig. 1a and supplemental Fig. S1a). To test the func-
tional significance of the NME2 occupancy, endogenous
hTERT expression was checked inNME2-overexpressed or -si-
lenced conditions in HT1080 and HCT116 cells. We found
clear repression and an increase in hTERT expression upon
NME2 overexpression or silencing, respectively, and similar
changes in hTERT protein levels (Fig. 1, b and c, and supple-
mental Fig. S1b). The core promoter of hTERTwas cloned into
a luciferase reporter, and promoter activity was measured
under NME2-altered conditions in HT1080 and HCT116
cells. NME2 expression and hTERT promoter activity were
found to be inversely correlated (Fig. 1, d and e). Together,
these data suggested NME2-mediated transcriptional re-
pression of hTERT in cancer cells.
This was further supported by fluorescence-activated cell
sorting (FACS) and immunofluorescence analysis using stable
NME2-overexpressing cells, which showed reduced expression
of hTERT relative to vector-transformed cells (Fig. 1f and sup-
plemental Fig. S1, c and d). Telomerase enzymatic activity was
measured under NME2-overexpressed or -silenced conditions
using a telomere repeat amplification protocol, and a reduc-
tion or an increase in telomerase activity, respectively, was
observed (supplemental Fig. S1e). Based on this, we asked
whether NME2 repressed hTERT in normal primary cells. In
primary lung fibroblast MRC5 cells, we found repression or
enhanced hTERT expression and promoter activity under
NME2-overexpressed or -silenced conditions, respectively
(Fig. 1, g and h).
To validate the occupancy ofNME2on the hTERTpromoter,
an oligonucleotide pulldown assay was performed. A puta-
tive 12-mer (115 to 127 bp from hTERT transcription
start site) representing the NME2 DNA-binding motif (23)
or its mutated/scrambled negative controls were used. Pull-
down using anti-NME2 antibody showed specific binding to
the unaltered (wild-type (WT)) relative to mutated (MUT)
or scrambled motifs (Fig. 1i). Furthermore, a reporter plas-
mid in which the mutant NME2 motif was inserted did not
suppress promoter activity in the presence of NME2 in
HT1080 and HCT116 cells (Fig. 1j). Together, these results
suggested that NME2 binding was required for transcrip-
tional repression of hTERT.
Next, we checked the role, if any, of NME1, a close homolog
of NME2, in transcriptional repression on hTERT. hTERT
expression and protein levels remained unaltered when NME1
was specifically silenced (supplemental Fig. S1, f and g); hTERT
promoter activity alsowas not affected uponNME1 silencing in
HT1080 cells (supplemental Fig. S1h).
NME2maintains repressive chromatin at the hTERT promoter
by engaging the REST–LSD1 repressor complex
To understand the mechanism underlying NME2-mediated
hTERT repression, we asked whether other binding partners of
NME2were involved. To find possible nuclear interacting part-
ners of NME2, we used LC-MS/MS after immunoprecipitation
with anti-NME2 antibody from nuclear extract of HT1080
cells. Using a stringent analysis cutoff of 1% false discovery rate,
120 interacting partners of NME2were detected (supplemental
Fig. S2a and Table S1) that belonged to several important
classes including chromatin remodeling (Gene Ontology anal-
ysis; supplemental Fig. S2b).Of these, to specifically understand
possible mechanisms underlying NME2-induced hTERT
repression, we focused on chromatin modifiers HDAC1 and
HDAC2. Interaction of NME2 with both HDAC1 and HDAC2
was further confirmed using co-immunoprecipitation (co-IP)
experiments (Fig. 2a).
HDAC1 and HDAC2 are integral members of the REST
repressor complex that engages the lysine-specific demethylase
LSD-1 (25, 26). Therefore, we checkedwhetherNME2 interacts
with REST and LSD1. Co-IP with anti-NME2 antibody showed
clear enrichment of REST and LSD1 in the anti-NME2-immu-
noprecipitated fraction compared with its isotype control IgG
(Fig. 2a). In addition, reverse co-IP with anti-REST or anti-
LSD1 confirmed NME2 interaction with REST–LSD1 (supple-
mental Fig. S2c).
Next, we checked for REST and LSD1 occupancy on the
hTERT promoter and determined whether this was NME2-de-
pendent. BothRESTandLSD1ChIPs showedoccupancy on the
hTERT promoter where the ChIP signals were significantly
reduced under NME2-silenced conditions (Fig. 2, b and c, and
supplemental Fig. S2d). We also found HDAC1 and HDAC2
occupancy on the hTERT promoter to be dependent on NME2
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(Fig. 2d). Moreover, sequential ChIP for NME2–REST and
NME2–LSD1 further supported co-occupancy of NME2–
REST–LSD1 complex on the hTERT promoter in HT1080 and
HCT116 cells (Fig. 2, e and f).
Next, we asked whether NME2-mediated engagement of
REST–LSD1 affected hTERT expression. siRNA against REST
attenuated NME2-induced repression of hTERT expression,
which was further derepressed using the LSD1 inhibitor tranyl-
cypromine (TCP) (Fig. 2g). Silencing of all three, NME2, REST,
and LSD1, led to a further increase in hTERT expression (Fig.
2g). An increase in hTERT expression and promoter activity
was also evident upon inhibition of REST and LSD1 indepen-
dently or together (supplemental Fig. S2, e and f). In addition,
histonemethylationChIP results showed an increase in histone
activation marks (H3K4me2 and H3K4me) following silencing
of REST (supplemental Fig. S2g). Taken together these results
show role of NME2 in promoting repressive chromatin at the
hTERT promoter through the REST–LSD1 complex to sup-
press hTERT expression.
Conversely, we expected permissive chromatin at the hTERT
promoter upon silencing NME2. We checked histone activa-
tionmarksH3K9ac,H3K4Me2, andH3K4Meand found that all
three marks were clearly enhanced in cells treated with siRNA
against NME2 relative to control cells (si-control), whereas
there was no significant change in total histone H3 occupancy
(Fig. 2h).
Figure1.NME2occupies thehTERTpromoterand reduces its expression.a, NME2ChIP showingoccupancyofNME2on thehTERTpromoter inHT1080and
HCT116 cell lines. ptprc gene serves as a negative control. b and c, real-time PCR (b) and Western blot analysis (c) for hTERT expression (49, 50) upon NME2
overexpressionandNME2 silencing inHT1080andHCT116cells. The toppanels showhTERTexpression, and the lower panels showtheexpressionof theGAPDH
loading control (c). Error bars represent S.E. (three biological replicates); * indicates a p value0.05; ** indicates a p value0.005. d and e, luciferase reporter
assay tomeasure hTERT promoter activity upon NME2-overexpressed (d) and -silenced conditions (e). F-luc, firefly luciferase; R-luc, Renilla luciferase. Error bars
represent S.E. (three biological replicates); * indicates a p value0.05; ** indicates a p value0.005. f, flow cytometry analysis shows reduced expression of
hTERT in GFP-NME2 stably overexpressing cells in comparison with GFP vector (Vec) HT1080 cells. Error bars represent S.E. (three biological replicates); *
indicates a p value0.05. g and h, hTERT expression (g) and promoter activity (h) were measured in primary MRC5 normal lung fibroblasts in NME2-overex-
pressed and -silenced conditions. Error bars represent S.E. (three biological replicates); * indicates a p value 0.05. i, oligo pulldown assay for NME2 using
biotin-labeled oligos with WT, MUT, and scrambled (Scr) NME2 motifs. The lower panel represents the loading control. j, luciferase reporter assay for hTERT
promoter activity after overexpressing NME2 along with wild-type and mutant NME2 motifs present in hTERT promoter construct. Error bars represent S.E.
(three biological replicates); * indicates a p value0.05.
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NME2mutants devoid of DNA-binding function are unable to
repress hTERT transcription
Mutants of NME2 that are unable to bind DNA (N69H and
R34A) were reported earlier (27, 28). Using these mutants,
we checked whether DNA binding by NME2 was required
for hTERT repression. Both the mutants, NME2(N69H) and
NME2(R34A), did not show any repression of hTERT expres-
sion or promoter activity in HT1080 cells (Fig. 3, a and b). This
was further confirmed using stable NME2 knockdown cells
(supplemental Fig. S3a). As expected, on stable knockdown of
NME2, telomerase expression and promoter activity increased
significantly (supplemental Fig. S3, b and c). hTERT repression
and reduced promoter activity were observed on inducing
HA-taggedNME2 (HA-NME2) but not whenHA-NME2(N69H)
or HA-NME2(R34A) were induced (Fig. 3, c and d, and supple-
mentalFig. S3d).Furthermore,using themutantNME2(N69H),we
checked whether occupancy of the REST–LDS1 complex was
altered vis-à-vis wild-type NME2. First, using ChIP with HA
antibody, we confirmed relatively reduced occupancy of the
NME2(N69H) mutant compared with wild-type NME2 on the
hTERT promoter (Fig. 3e). Next, using ChIP, we observed
reduced occupancy of REST at the hTERT promoter in the case
of NME2(N69H) compared with NME2 (Fig. 3f) that was not
due to any loss of REST interaction with the mutant
NME2(N69H) as shown by co-IP experiments in HT1080 cells
(Fig. 3g). Consistent with reduced REST occupancy, we further
found both LSD1 and HDAC1 occupancy to be reduced at the
hTERT promoter in the case of NME2(N69H) relative to wild-
type NME2 (Fig. 3f). Together, these studies confirmed DNA
binding by NME2 to be a key factor in occupancy of the REST–
LSD1 complex at the hTERT promoter and hTERT repression
by NME2.
G-quadruplexmotif at the hTERT promoter was required for
NME2 and REST–LSD1 occupancy at the hTERT promoter
Potential G4 (PG4)-forming sequences were reported in the
hTERT promoter (29, 51). Interestingly, we observed that the
NME2-binding motif (Fig. 4a) was within also within a hTERT
promoter PG4-forming sequence, and because NME2 and pro-
moter G4 interactions have been reported before (21, 30), we
asked whether the G4 structure played any role in hTERT
repression by NME2. Oligonucleotide representing the PG4-
forming sequence adopted mixed parallel/antiparallel G4
structures in solution (Fig. 4b). For further work, we designed
nucleotide substitutions such that key bases required for G4
stability were mutated, but the NME2-binding motif remained
intact. This resulted in a disruptedG4 structure in solution (Fig.
4b). Next, a luciferase reporter construct was made by substi-
tuting these bases (MUT-G4) using site-directed mutagenesis.
Upon expression of NME2, although promoter activity was
repressed by50% in the case of the G4-containing construct,
for MUT-G4 the observed repression was relatively less in
HT1080 and HCT116 cells (Fig. 4c).
To test NME2 interaction with the G4, we used oligonucle-
otide pulldown with the G4 or the MUT-G4 sequence. On
probing with anti-NME2 antibody, we found relatively reduced
affinity of NME2 toward the MUT-G4 compared with G4 (Fig.
4d and supplemental Fig. S4). In addition, we checked and
observed that a significantly reduced amount of REST was
pulled down in the case of MUT-G4, supporting NME2–REST
interaction (Fig. 4d). Furthermore, we found reduced intracel-
lular occupancy of NME2 at the hTERT promoter in the case of
ectopically maintained MUT-G4 relative to G4 in ChIP with
anti-NME2 antibody followed by PCR with plasmid-specific
primers (Fig. 4e; also called transient ChIP (31)). This was also
confirmed by ChIP using anti-REST or anti-LSD1 where
reduced occupancy was observed for both REST and LSD1 on
the hTERT promoter in the case ofMUT-G4 (Fig. 4f). Together,
these results support roles of the G4 structural motif in NME2
binding and recruitment of the REST–LSD1 complex for
hTERT repression.
We next studied the effect of G4-binding ligands on telom-
erase transcription. BecauseG4 ligandswere noted to both acti-
vate and repress gene transcription (32, 52), we screened 20
previously established intracellular G4-binding ligands (listed
in supplemental Table S2). Of these, 11 ligands showed down-
regulation (50–85%) of hTERT in HT1080 cells (Fig. 4g and
supplemental Table S2). Five of the 11 ligands also showed
more than 50% reduction in hTERT promoter activity in
reporter assays (Fig. 4h), and the ligand-induced effect on pro-
moter activity was lost in the case of all five ligandswhen theG4
motif was mutated in the reporter construct. This further sup-
ported a role of G4–ligand interactions inside cells in hTERT
repression (Fig. 4h).
Discussion
Multiple transcription factors including Sp1, c-Myc, p53,
SP1, ETS, E2F, and AP1 have been reported to transcriptionally
control hTERT expression (10, 33, 34). However, how these
function to control the epigenetic state of the hTERT promoter
is not precisely understood. For example, histone deacetylation
repressed hTERT transcription, whereas treatment with the
HDAC inhibitor trichostatin A resulted in activation of hTERT
(35), and a recent report suggested that LSD1, using its demeth-
ylation activity, altered activating histone marks on the hTERT
promoter to repress hTERT transcription (36). Although these
studies indicated the participating regulatory factors, mecha-
Figure 2. NME2 interactswith REST complex andalters chromatinmarks onhTERT to repress transcription. a, co-IP assay for validation of REST complex
component interaction with NME2 as obtained from LC-MS/MS results. Co-IP for REST, LSD1, HDAC1, and HDAC2 was performed using nuclear extract from
HT1080 cells.b–d, LSD1 (b), REST (c), andHDAC1/2 (d) ChIP in theNME2 transiently silenced condition showing reducedoccupancyon thehTERTpromoter. The
histogram represents the -fold change in LSD1, REST, and HDAC1/2 occupancy on the hTERT promoter. Error bars represent S.E. (three biological replicates); *
indicates a p value0.05. e and f, sequential chromatin immunoprecipitation for NME2–LSD1 (e) and NME2–REST (f) followed by PCR of hTERT promoter in
HT1080 and HCT116 cell lines. g, hTERT mRNA expression was measured after silencing of REST and NME2, blocking of LSD1 using TCP, and combinations of
both treatments. Error bars represent S.E. (three biological replicates); * indicates a p value 0.05; ** indicates a p value 0.005. h, ChIP for active histone
methylation (H3K4me andH3K4me2) and acetylation (H3K9ac)marks and total histone3 (H3) on hTERTpromoter in NME2-silenced conditions in HT1080 cells.
Scr, scrambled.
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nisms of how the repressors/histonemodifierswere engaged on
the hTERT promoter have remained unclear.
Herein we show that NME2 transcriptionally represses
hTERT through recruitment of the REST repressor complex,
which includes REST, HDAC1, HDAC2, and LSD1. Using
direct and sequential ChIP, we found that association of the
REST repressor complex on the hTERT promoter was depen-
dent on NME2. Moreover, co-immunoprecipitation experi-
ments confirmed that NME2 interacted with members of the
REST complex inside the nucleus. As a result, we observed that
the hTERT promoter is maintained in a repressive chromatin
state. In other words, these data suggest that the loss of NME2
results in permissive chromatin at the hTERT promoter and
up-regulation of hTERT expression.
Figure 3. hTERT transcription repression is dependent onDNAbinding byNME2. a and b, hTERTmRNA (a) and promoter activity (b) following expression
of HA-tagged proteins HA-NME2, HA-NME2(N69H), and HA-NME2(R34A) (R34A andN69H arewell-characterized NME2mutants lacking DNA-binding activity)
or the HA vector (Vec) control in HT1080 cells; GAPDH was used as a control for mRNA expression. Error bars represent S.E. (three biological replicates); *, p
0.05; **, p 0.005. c and d, in a stable NME2-silenced background, hTERTmRNA (c) and promoter activity (d) were checked upon independent overexpression
of HA-NME2, HA-NME2(N69H), HA-NME2(R34A), or the HA vector control; GAPDH was used as a control for mRNA expression. Error bars represent S.E. (three
biological replicates); *, p 0.05; **, p 0.005. e, occupancy at the hTERT promoter was reduced in the case of HA-NME2(N69H) relative to HA-NME2 following
ChIP using anti-HA antibody. f, occupancy of the components of the REST repressor complex (REST, LSD1, and HDAC1) at the hTERT promoter was reduced in
cells overexpressing HA-NME2(N69H) relative to cells expressing HA-NME2. g, NME2/mutant co-IP with REST. Nuclear lysate prepared from cells expressing
either HA-NME2 or HA-NME2(N69H) immunoprecipitated with anti-HA antibody (top panel) was probed with anti-REST antibody; total anti-HA was used as a
loading control (lower panel).
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Figure 4. Repression of hTERT depends on NME2 interaction with hTERT promoter G-quadruplex. a, minimal promoter of hTERT showing the NME2-
binding site (gray solid bar) and PG4-forming sequence (underlined). b, circular dichroism plot showing formation of the G4 motif in solution, whereas the
sequence with mutations in key bases (MUT-G4) showed partial disruption of the G4 motif under similar conditions. TSS, transcription start site. c, luciferase
reporter assay for hTERT promoter activity upon transfection of either the wild-type G4 or the disruptedMUT-G4 plasmid alongwith HA vector or HA-NME2 in
HT1080 and HCT116 cells. F-luc, firefly luciferase; R-luc, Renilla luciferase. Error bars represent S.E. (three biological replicates); * indicates p 0.05. d, oligonu-
cleotide pulldown assay with either the WT G4 or the disrupted MUT-G4 oligonucleotide in HT1080 nuclear lysate developed with the respective antibodies
shows that both NME2 and REST have enhanced affinity for the G4 motif relative to MUT-G4. e and f, intracellular NME2 (and REST–LSD1) occupancy at the
hTERTpromoter and thepresenceof intact/deformedpromoterG4motif. ChIPusingplasmidvectorsharboring thehTERTpromoter (Transient ChIP) shows that
NME2 (e) and REST–LSD1 (f) occupancy at the hTERT promoter was significantly lost in the case of the plasmidwith the disrupted G4motif (MUTG4) relative to
theplasmidwith theWTG4motif inHT1080 cells. ChIP-PCRwasperformedusingprimers specific for theplasmid.g,hTERT expression inHT1080 cells following
treatment with G-quadruplex–binding ligands. Error bars represent S.E. (three biological replicates); * indicates p 0.05. h, effect of selected G-quadruplex–
binding ligands on hTERTpromoter activity in the case of reporter vectorwith either the intact G4motif (WTG4) or the disruptedG4motif (MUT-G4) in HT1080
cells. Error bars represent S.E. (three biological replicates); * indicates p 0.05.
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Low NME2 has been associated with malignant transforma-
tion in multiple cancers (14, 18). Independently, in oral, breast,
and colon cancer, mechanisms of antimetastatic action of
NME2 were suggested to be through induction of the epithelial
phenotype (mesenchymal to epithelial transition) (37). Con-
versely, increased telomerase due to telomerase reactivation
was noted in progression of various cancers including acute
leukemia, breast, prostate, lung, and melanoma (38). Recent
studies further reveal that point mutations in the hTERT pro-
moter leading to increased hTERT mRNA synthesis is key to
hTERT reactivation in several cancers (10, 39). In this context,
possible implications of low NME2 in up-regulation of hTERT
transcription through epigenetic alteration of the hTERT pro-
moter could be of interest in understanding mechanisms of
telomerase activation. Although results suggest engagement of
the repressor complex in anNME2-dependentmanner, further
studies will be required to understand how other transcription
factors at the hTERT promoter influence this mechanism.
NME2 was also noted to inhibit telomerase catalytic activity in
vitro (40). Together with findings reported here, this indicates a
possible dual role of NME2 in control of telomerase in cancer
cells.
Multiple lines of evidence support a role of G4motifs in gene
expression. Prominent among these are enrichment of poten-
tial G4 forms within promoters across species (41–43) and evi-
dence supporting their role in gene expression (44) including
their presence in vivo and identification of proteins that func-
tion in association with G4s inside cells (45–48). Interestingly,
NME2 was reported to regulate transcription through interac-
tion with a c-myc promoter G4motif (21). Together, these data
prompted a closer look when we noted that the hTERT pro-
moter harbors G4-forming sequences that were implicated in
possible hTERT expression (29). Our results support a role of
hTERT promoterG4motifs in hTERT repression. This encour-
aged us to test G4 ligand-mediated repression of hTERT
expression, which in turn may open potential ways of control-
ling hTERT activation in cancer cells.
Experimental procedures
Cells and culture conditions
HT1080, HCT116, and MRC5 primary fibroblast cells were
obtained from the American Type Cell Culture (ATCC) and
maintained in modified Eagle’s medium (MEM), Dulbecco’s
modified Eagle’s medium low glucose (DMEM) with high glu-
cose, andMEM, respectively, and supplemented with 10% fetal
bovine serum at 37 °C in 5% CO2.
ChIP
ChIP assays were performed as described (40) with the fol-
lowing antibodies: rabbit anti-HA antibody (Abcam, ab9110),
anti-rabbit IgG (Sigma), anti-REST antibody (Millipore, 17641),
anti-LSD1 (Abcam, ab17721), anti-HDAC1 (Abcam, ab7028), anti-
HDAC2(Abcam,ab51832),anti-H3K4me (Abcam, ab8895), anti-
H3K4me2 (Abcam, ab7766), anti-H3K4me3 (Abcam, ab8580),
anti-histone3 (Abcam, ab1791), and anti-H3k9ac (Abcam,
ab10812). For sequential ChIP, samples were treated as
described for ChIP (40) before adding 3–4 g of the first anti-
body and incubating overnight at 4 °C followed by 50l of pro-
tein G-Sepharose beads for 4 h at 4 °C on a rotator. Samples
were then washed with washing buffers (low-salt buffers, high-
salt buffers, and lithium chloride) and divided into two frac-
tions. One part was processed further for ChIP-DNA elution,
and 3–4 g of the second antibody was added to the second
fraction and incubated again overnight at 4 °C followed by incu-
bation with 50 l of protein G-Sepharose beads. Beads were
washed (washing buffers as above), and the final DNA samples
were obtained using a phenol, chloroform, and isoamyl alcohol
precipitation method (as for basic ChIP protocol). The ChIP
PCR primers used for hTERT promoter were 5-CCAGGCCG-
GGCTCCCAGTGGAT-3 (forward) and 5-GGCTTCCCAC-
GTGCGCAGCAGGA-3 (reverse), and the amplicon length
was 275 bp. For transient ChIP assays, cells were transfected
withwild-type hTERT andmutant hTERT promoter constructs
(2g of plasmid/1 106cells). Transfected cells were harvested
after 48 h, and ChIP was performed against REST, NME2, and
LSD1 as described above. The eluted ChIP-DNA was checked
for hTERT promoter amplification by using primers derived
partially from the vector construct and from the hTERT pro-
moter sequence.
Real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen,
Life Technologies) according to the manufacturer’s instruc-
tions. RNAwas quantified, and 2g of RNAwas used for cDNA
preparation using anApplied Biosciences kit. The relative tran-
script expression level for genes was measured by quantitative
real-time PCR using a SYBR Green-based method. Average
-fold changewas calculated by the difference in threshold cycles
(Ct) between test and control samples. GAPDH gene was used
as an internal control for normalizing the cDNA concentration
of each sample. For TCP (concentration, 1 M)-treated cells,
treatment was done after 24 h of transfection, and RNA was
isolated 24 h post-treatment. G-quadruplex ligand (concentra-
tion, 2 M) treatment was done for 48 h.
siRNA transfection
SMARTpool ON-TARGET siRNAs against NME2, NME1,
and REST were procured from GE Dharmacon and used
according to the manufacturer’s protocol.
Luciferase assay
The minimal promoter region of hTERT harboring the
NME2 motif and G-quadruplex sequences was cloned into
pGL3-basic vector and transfected into HT1080 and HCT116
cells using Lipofectamine 2000 (Invitrogen). Plasmid (pGL4.73)
containing a CMV promoter driving Renilla luciferase was co-
transfected as a transfection control for normalization. After
48 h, cells were harvested, and luciferase activities of cell lysate
were measured using a Dual-Luciferase reporter assay kit (Pro-
mega). For TCP (concentration, 1 M)-treated cells, treatment
was done after 24 h of transfection, and luciferase activity was
measured 24 h post-treatment. G-quadruplex ligand (concen-
tration, 2 M) treatment was done for 48 h.
Preparation of nuclear extracts
HT1080 cells grown in MEM supplemented with 10% FBS
(Sigma) were collected andwashed in cold 1 PBS, and nuclear
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extract was isolated using a nuclear extraction kit (CelLytic,
Sigma) according to the manufacturer’s protocol.
Co-IP
For immunoprecipitation experiments, 500 g of nuclear
extract was incubated for 4 h at 4 °C with 4 g of anti-NME2
antibody (Kamiya, KM1121 MC412). Immunoprecipitation
was performed using a Catch and Release co-immunoprecipi-
tation kit (Millipore) according to the manufacturer’s protocol.
Antibodies andWestern blotting
For Western analysis, immunoprecipitated nuclear extracts
were separated by 10% sodium dodecyl sulfate (SDS)-PAGE
and transferred to polyvinylidene difluoride (PVDF) mem-
branes (Immobilon FL, Millipore). The following primary
antibodies were used for immunoblotting: anti-REST antibody
(Millipore, 17–641), anti-HDAC1 (Abcam, ab7028), anti-
HDAC2 (Abcam, ab51832), anti-LSD1 (Abcam, ab17721), anti-
NME2 (Abcam, ab60602) (23, 24, 40), and anti-hTERT (Abcam,
ab32020) (49, 50). The secondary antibodies used were anti-
mouse and anti-rabbit alkaline phosphatase conjugates from
Sigma. Western blots with antibodies against NME2, telomer-
ase, REST, and LSD1 along with relevant molecular weight
markers are shown in supplemental Fig. S5.
Immunofluorescencemicroscopy
Cells were grown on coverslips and at 100% confluence were
fixed with 4% paraformaldehyde by incubating for 10 min at
room temperature. Cells were permeabilized with 0.5% Tri-
tonTM X-100 and treated with blocking solution (3% BSA in
PBS) for 30min at room temperature. After one PBS (1) wash,
cells were treated with anti-hTERT antibody (1:100) overnight
at 4 °C. The next day cells were washed alternately with 1 PBS
and PBS with Tween 20 three times and probed with Alexa
Fluor 594 for 1 h at room temperature. Cells were washed
again alternately with PBS and PBS with Tween 20 three times
and mounted with Prolong Gold antifade reagent with DAPI.
Imageswere taken asmaximum intensity projections on a Leica
TCS-SP8 confocal microscope.
Flow cytometry (FACS)
After trypsinization, both stable GFP-NME2-expressing and
corresponding GFP vector-transformed cells were fixed in 4%
paraformaldehyde for 10 min. After washing in PBS, cells were
permeabilized in 0.5% Triton X-100 in PBS for 10 min. After
blocking in 3%BSA in PBS for 1 h at 4 °C followed bywashing in
PBS, cells were incubated with primary anti-hTERT antibody
(Abcam, ab94523) (1:100) at 4 °C overnight. After washing in
PBS, cells were incubatedwithAlexa Fluor 594-conjugated sec-
ondary antibody for 2 h at 4 °C. As a negative control, cells were
fixed and incubated with secondary antibody only without
incubation with primary antibody. Finally, after washing in
PBS, cells were resuspended in PBS for acquisition by flow
cytometry (BD Biosciences FACSAria III) using the Cy3 chan-
nel (for Alexa Fluor 594) to detect hTERT expression.
Oligonucleotide pulldown assay
For pulldown assays, 2g of biotinylated NME2motif, motif
mutant M1, wild-type G4, andMUT-G4 and 300 g of nuclear
extract (prepared fromHT1080 cells) were incubated for 1 h at
room temperature in binding buffer. Then the whole complex
was incubated with 60 l of streptavidin-agarose (Invitrogen)
for 4 h at 4 °C. In all experiments, the beads were washed three
times with washing buffer (50 mM Tris-HCl (pH 7.5) and 150
mMNaCl), and the bound proteins were eluted by boiling in 5
SDS sample buffer (20 mM Tris-HCl (pH 6.8), 10% glycerol, 4%
SDS, 100 mM dithiothreitol, 4 mM EDTA, and 0.025% Coomas-
sie Brilliant Blue R-250) and subjected toWestern blot analysis
using anti-REST antibody (Abcam) and anti-NME2 antibody
(Kamiya).
Separation of immunoprecipitate and preparation of peptide
mixtures
Protein identification using mass spectrometry was per-
formed as follows. First, the immunoprecipitatewas resolved by
12.5% SDS-PAGE followed by visualization with colloidal Coo-
massie Brilliant Blue. The bands that appeared specifically in
the immunoprecipitate were excised manually using sterile
blades. Further procedures including distaining and digestion
with trypsin followed by extraction of peptides were performed
manually. In brief, gel pieces were distained in 50 mM ammo-
nium bicarbonate and acetonitrile (50%, v/v) and dehydrated
with 95% (v/v) acetonitrile. The dehydrated gel pieces were
soaked with a sufficient volume of trypsin solution (20 ng/l
trypsin in 25 mM ammonium bicarbonate) and incubated at
37 °C overnight. Upon digestion, the trypsinized solution was
pooled with a further peptide extraction from gel pieces using
50% (v/v) acetonitrile containing 0.1% (v/v) acetic acid and
incubating for 30 min at 37 °C with constant shaking. The pep-
tide extract collected as supernatant was pooled, vacuum-dried
to about 10 l, and purified using a micro ZipTip (Millipore).
The purified mixture was vacuum-dried, and peptides were
reconstituted in 2% acetonitrile containing 0.1% (v/v) acetic
acid and further analyzed by LC-MS/MS.
Identification of proteins using LC-MS/MS
Protein identification from peptide mixtures was performed
on an LTQ Orbitrap Velos mass spectrometer (Thermo Scien-
tific, Germany) equipped with a nanoelectrospray ion source
coupledwith an on-line Proxeon Easy nLC (Thermo Scientific).
Briefly, the peptides were separated using an Acclaim PepMap
100 analytical column (C18; particle size, 3 m; 75-m inner
diameter; 15 cm long; 100 Å; LC Packings, Germany) at a flow
rate of 300 nl/min. Before separation, the peptide mixtures
were enriched using an NS-MP-10 Biosphere precolumn (C18;
particle size, 5 m; 100-m inner diameter; 20 mm long; pore
size, 120Å;Nano Separations, Netherlands). The peptideswere
eluted with a mixture of solvent gradient (2–5% buffer B in 1
min, 5–25% buffer B in 59min, 25–40% buffer B in 10min, and
100% buffer B in 8 min) of buffer A (2% acetonitrile containing
0.1% acetic acid) and buffer B (acetonitrile containing 0.1% ace-
tic acid). The eluted peptides were electrosprayed into themass
spectrometer. The mass spectrometric data were collected in
data-dependent mode to switch between Orbitrap MS and
LTQ MS/MS acquisition automatically. Full-scan MS spectra
in them/z range from 300 to 1700 (resolution r 30,000) were
acquired in the Orbitrap mass spectrometer. The data acquisi-
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tion method was set to isolate up to 20 of the most intense ions
depending upon signal intensity for fragmentation in the linear
ion trap using collision-induced dissociation. Target ions
already selected forMS/MSwere dynamically excluded for 60 s.
The general conditions of the mass spectrometer for data col-
lection were 1.6–1.7-kV electrospray voltage and ion selection
threshold of 2000 counts for MS/MS. For identification of pro-
teins from MS data, an automated database search was per-
formed using Proteome Discoverer 1.3.0.339 (Thermo Scien-
tific) with the Sequest algorithm. A human UniProt FASTA
database and a decoy database of 1% false discovery rate were
used for identification. Two possible missed cleavages for tryp-
sin enzyme specificity with a mass tolerance of 10 ppm (parent
ion) and 0.8 Da (fragment ion) and methionine oxidation
dynamics were considered for the database search. The identity
of the proteins was confirmed based on high-confidence pep-
tide identification containing at least two peptides per protein
(with rank 1 peptides in proteins; XCorr score,2.45 or 2.85 for
doubly and triply charged peptides, respectively).
Site-directedmutagenesis
A QuikChange site-directed mutagenesis kit (Agilent tech-
nologies) was used to generate various mutants ofNME2 gene.
Mutagenesis reactions were performed according to the man-
ufacturer’s instructions with the wild-type c-DNA cloned in
pRSET-Aused as a template. The positive cloneswere screened
for the mutation by sequencing.
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